Publication | Open Access

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

MedicineMetronomic TherapyPharmacologyPathologyDifferential Antitumor EffectsMet AlterationsBronchial NeoplasmAnti-cancer AgentCancer TreatmentLung CancerOncologyTumor MicroenvironmentTumor Biology